ISRCTN57359805 https://doi.org/10.1186/ISRCTN57359805

# Phase I trial, Quotient Code: QSC300720

| | | |
|---|---|---|
| **Submission date**<br>14/07/2023 | **Recruitment status**<br>No longer recruiting | [X] Prospectively registered<br>[_] Protocol<br>[_] Statistical analysis plan<br>[_] Results<br>[_] Individual participant data<br>[_] Record updated in last year |
| **Registration date**<br>19/07/2023 | **Overall study status**<br>Deferred | |
| **Last Edited**<br>19/07/2023 | **Condition category**<br>Other | |

**Plain English summary of protocol**
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

## Contact information

**Type(s)**
Principal Investigator

**Contact name**
Dr Phil Evans

**Contact details**
Quotient Sciences Limited
Mere Way
Ruddington Fields
Ruddington
Nottingham
United Kingdom
NG11 6JS
+44 (0)330 303 1000
recruitment@weneedyou.co.uk

**Type(s)**
Scientific

**Contact name**
Dr Phil Evans

**Contact details**
Quotient Sciences Limited
Mere Way
Ruddington Fields

Ruddington
Nottingham
United Kingdom
NG11 6JS
+44 (0)330 300 1000
recruitment@weneedyou.co.uk

### Type(s)
Public

### Contact name
Dr Phil Evans

### Contact details
Quotient Sciences Limited
Mere Way
Ruddington Fields
Ruddington
Nottingham
United Kingdom
NG11 6JS
+44 (0)330 303 1000
recruitment@weneedyou.co.uk

## Additional identifiers

### EudraCT/CTIS number
Nil known

### IRAS number
1007785

### ClinicalTrials.gov number
Nil known

### Secondary identifying numbers
IRAS 1007785

## Study information

### Scientific Title
Phase I trial, Quotient Code: QSC300720 [The full scientific title will be published within 30 months after the end of the trial]

### Study objectives
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

### Ethics approval required

Ethics approval required

## Ethics approval(s)
1. Submitted 06/07/2023, London Surrey Borders REC (2nd Floor 2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 (0)207 104 8057; Surreyborders.rec@hra.nhs.uk), ref: 23/LO/0521

2. Submitted 06/07/2023, MHRA (10 South Colonnade, Canary Wharf, London , E14 4PU, United Kingdom; +44 (0)20 3080 6000; info@mhra.gov.uk), ref: CTA 58311/0001/001-0001

## Study design
One-part single-centre non-randomized open-label study

## Primary study design
Interventional

## Secondary study design
Non randomised study

## Study setting(s)
Pharmaceutical testing facility

## Study type(s)
Other

## Participant information sheet
Not available in web format

## Health condition(s) or problem(s) studied
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

## Interventions
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

## Intervention Type
Drug

## Pharmaceutical study type(s)
Pharmacokinetic

## Phase
Phase I

## Drug/device/biological/vaccine name(s)
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

### Primary outcome measure
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

### Secondary outcome measures
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

### Overall study start date
06/07/2023

### Completion date
16/02/2024

## Eligibility

### Key inclusion criteria
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

### Participant type(s)
Healthy volunteer

### Age group
Adult

### Sex
Both

### Target number of participants
16

### Key exclusion criteria
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

### Date of first enrolment
27/09/2023

### Date of final enrolment
16/02/2024

## Locations

### Countries of recruitment

England

United Kingdom

**Study participating centre**
**Quotient Sciences Limited**
Mere Way
Ruddington Fields
Ruddington
Nottingham
United Kingdom
NG11 6JS

# Sponsor information

**Organisation**
Veradermics Inc

**Sponsor details**
85 Memorial Road, #415
West Hartford
United States of America
CT 06107
+1 847 641 0412
tdurso@veradermics.com

**Sponsor type**
Industry

**Website**
https://www.veradermics.com/

# Funder(s)

**Funder type**
Industry

**Funder Name**
Veradermics Inc

# Results and Publications

## Publication and dissemination plan
Full trial details will be published up to 30 months after the end of the trial. Publication of some trial details is deferred because of the high commercial sensitivity of this phase I study and the negligible benefit to the public of phase I information. Results will be posted on or after the date of publication of full trial details.

## Intention to publish date
16/08/2026

## Individual participant data (IPD) sharing plan
The datasets generated and/or analysed during the current study are not expected to be made available because of their high commercial sensitivity and the negligible benefit to the public of publication of results of non-therapeutic clinical trials.

## IPD sharing plan summary
Not expected to be made available